1
|
Rouleau M, Villeneuve L, Allain EP, McCabe-Leroux J, Tremblay S, Nguyen Van Long F, Uchil A, Joly-Beauparlant C, Droit A, Guillemette C. Non-canonical transcriptional regulation of the poor prognostic factor UGT2B17 in chronic lymphocytic leukemic and normal B cells. BMC Cancer 2024; 24:410. [PMID: 38566115 PMCID: PMC10985967 DOI: 10.1186/s12885-024-12143-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2023] [Accepted: 03/19/2024] [Indexed: 04/04/2024] Open
Abstract
BACKGROUND High expression of the glycosyltransferase UGT2B17 represents an independent adverse prognostic marker in chronic lymphocytic leukemia (CLL). It also constitutes a predictive marker for therapeutic response and a drug resistance mechanism. The key determinants driving expression of the UGT2B17 gene in normal and leukemic B-cells remain undefined. The UGT2B17 transcriptome is complex and is comprised of at least 10 alternative transcripts, identified by previous RNA-sequencing of liver and intestine. We hypothesized that the transcriptional program regulating UGT2B17 in B-lymphocytes is distinct from the canonical expression previously characterized in the liver. RESULTS RNA-sequencing and genomics data revealed a specific genomic landscape at the UGT2B17 locus in normal and leukemic B-cells. RNA-sequencing and quantitative PCR data indicated that the UGT2B17 enzyme is solely encoded by alternative transcripts expressed in CLL patient cells and not by the canonical transcript widely expressed in the liver and intestine. Chromatin accessible regions (ATAC-Seq) in CLL cells mapped with alternative promoters and non-coding exons, which may be derived from endogenous retrotransposon elements. By luciferase reporter assays, we identified key cis-regulatory STAT3, RELA and interferon regulatory factor (IRF) binding sequences driving the expression of UGT2B17 in lymphoblastoid and leukemic B-cells. Electrophoretic mobility shift assays and pharmacological inhibition demonstrated key roles for the CLL prosurvival transcription factors STAT3 and NF-κB in the leukemic expression of UGT2B17. CONCLUSIONS UGT2B17 expression in B-CLL is driven by key regulators of CLL progression. Our data suggest that a NF-κB/STAT3/IRF/UGT2B17 axis may represent a novel B-cell pathway promoting disease progression and drug resistance.
Collapse
Affiliation(s)
- Michèle Rouleau
- Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec Research Center - Université Laval (CRCHUQc- UL), Université Laval, Québec, QC, Canada
- Cancer research center of Université Laval, Québec, Canada
| | - Lyne Villeneuve
- Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec Research Center - Université Laval (CRCHUQc- UL), Université Laval, Québec, QC, Canada
- Cancer research center of Université Laval, Québec, Canada
| | - Eric P Allain
- Molecular Genetics Laboratory, Vitalité Health Network, Dr. Georges-L.-Dumont University Hospital Center, Moncton, NB, Canada
| | - Jules McCabe-Leroux
- Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec Research Center - Université Laval (CRCHUQc- UL), Université Laval, Québec, QC, Canada
- Cancer research center of Université Laval, Québec, Canada
| | - Sophie Tremblay
- Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec Research Center - Université Laval (CRCHUQc- UL), Université Laval, Québec, QC, Canada
- Cancer research center of Université Laval, Québec, Canada
| | - Flora Nguyen Van Long
- Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec Research Center - Université Laval (CRCHUQc- UL), Université Laval, Québec, QC, Canada
- Cancer research center of Université Laval, Québec, Canada
| | - Ashwini Uchil
- Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec Research Center - Université Laval (CRCHUQc- UL), Université Laval, Québec, QC, Canada
- Cancer research center of Université Laval, Québec, Canada
| | - Charles Joly-Beauparlant
- Cancer research center of Université Laval, Québec, Canada
- CRCHUQc-UL and Faculty of Medicine, Université Laval, Québec, Québec, Canada
| | - Arnaud Droit
- Cancer research center of Université Laval, Québec, Canada
- CRCHUQc-UL and Faculty of Medicine, Université Laval, Québec, Québec, Canada
| | - Chantal Guillemette
- Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec Research Center - Université Laval (CRCHUQc- UL), Université Laval, Québec, QC, Canada.
- Cancer research center of Université Laval, Québec, Canada.
- Canada Research Chair in Pharmacogenomics, Faculty of Pharmacy, Université Laval, Québec, QC, Canada.
| |
Collapse
|
2
|
Wajnberg G, Allain EP, Roy JW, Srivastava S, Saucier D, Morin P, Marrero A, O’Connell C, Ghosh A, Lewis SM, Ouellette RJ, Crapoulet N. Application of annotation-agnostic RNA sequencing data analysis tools for biomarker discovery in liquid biopsy. Front Bioinform 2023; 3:1127661. [PMID: 37252342 PMCID: PMC10213969 DOI: 10.3389/fbinf.2023.1127661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Accepted: 04/17/2023] [Indexed: 05/31/2023] Open
Abstract
RNA sequencing analysis is an important field in the study of extracellular vesicles (EVs), as these particles contain a variety of RNA species that may have diagnostic, prognostic and predictive value. Many of the bioinformatics tools currently used to analyze EV cargo rely on third-party annotations. Recently, analysis of unannotated expressed RNAs has become of interest, since these may provide complementary information to traditional annotated biomarkers or may help refine biological signatures used in machine learning by including unknown regions. Here we perform a comparative analysis of annotation-free and classical read-summarization tools for the analysis of RNA sequencing data generated for EVs isolated from persons with amyotrophic lateral sclerosis (ALS) and healthy donors. Differential expression analysis and digital-droplet PCR validation of unannotated RNAs also confirmed their existence and demonstrates the usefulness of including such potential biomarkers in transcriptome analysis. We show that find-then-annotate methods perform similarly to standard tools for the analysis of known features, and can also identify unannotated expressed RNAs, two of which were validated as overexpressed in ALS samples. We demonstrate that these tools can therefore be used for a stand-alone analysis or easily integrated into current workflows and may be useful for re-analysis as annotations can be integrated post hoc.
Collapse
Affiliation(s)
| | - Eric P. Allain
- Atlantic Cancer Research Institute, Moncton, NB, Canada
- Department of Clinical Genetics, Vitalité Health Network, Dr. Georges-L.-Dumont University Hospital Centre, Moncton, NB, Canada
- Department of Chemistry and Biochemistry, Université de Moncton, Moncton, NB, Canada
- Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada
| | - Jeremy W. Roy
- Atlantic Cancer Research Institute, Moncton, NB, Canada
- Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada
| | | | - Daniel Saucier
- Department of Chemistry and Biochemistry, Université de Moncton, Moncton, NB, Canada
| | - Pier Morin
- Department of Chemistry and Biochemistry, Université de Moncton, Moncton, NB, Canada
| | - Alier Marrero
- Dr. Georges-L.-Dumont University Hospital Centre, Moncton, NB, Canada
| | | | - Anirban Ghosh
- Atlantic Cancer Research Institute, Moncton, NB, Canada
| | - Stephen M. Lewis
- Atlantic Cancer Research Institute, Moncton, NB, Canada
- Department of Chemistry and Biochemistry, Université de Moncton, Moncton, NB, Canada
- Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada
| | - Rodney J. Ouellette
- Atlantic Cancer Research Institute, Moncton, NB, Canada
- Department of Chemistry and Biochemistry, Université de Moncton, Moncton, NB, Canada
- Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada
- Dr. Georges-L.-Dumont University Hospital Centre, Moncton, NB, Canada
| | | |
Collapse
|
3
|
LeBreton L, Allain EP, Parscan RC, Crapoulet N, Almaghraby A, Ben Amor M. A novel CHD3 variant in a patient with central precocious puberty: Expanded phenotype of Snijders Blok-Campeau syndrome? Am J Med Genet A 2023; 191:1065-1069. [PMID: 36565043 DOI: 10.1002/ajmg.a.63096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Revised: 12/12/2022] [Accepted: 12/13/2022] [Indexed: 12/25/2022]
Abstract
Snijders Blok-Campeau syndrome is an autosomal dominant genetic disorder first described in 2018, mostly associated with de novo variants in the CHD3 gene that affects chromatin remodeling. This syndrome is characterized by developmental delay, speech delay, and intellectual disability, but only about 60 affected individuals have been reported to date. We report a de novo likely pathogenic CHD3 variant (c.5609G > A; p. (Arg1870Gln)) in a young female presenting with features of Snijders Blok-Campeau syndrome including speech delay, autism spectrum disorder, learning difficulties, characteristic facial dysmorphisms, and a feature not previously described in this syndrome, idiopathic central precocious puberty. Her puberty was controlled with monthly injections of a GnRH analogue. Targeted exome sequencing was negative for genes known to be responsible for central precocious puberty. Our case raises the possibility that variants in CHD3 gene may also result in central precocious puberty. Strengthening this association could expand the phenotypic spectrum of the Snijders Blok-Campeau syndrome and should be included in multigene panels for precocious puberty.
Collapse
Affiliation(s)
- Laure LeBreton
- Centre de Formation Médicale du Nouveau-Brunswick, Université de Sherbrooke, Moncton, New Brunswick, Canada
| | - Eric P Allain
- Vitalité Health Network, Dr. Georges-L.-Dumont University Hospital Centre, Department of Medical Genetics, Moncton, New Brunswick, Canada.,Atlantic Cancer Research Institute, Pavillon Hôtel-Dieu, Moncton, New Brunswick, Canada.,Department of Chemistry and Biochemistry, Université de Moncton, New Brunswick Center for Precision Medicine, Moncton, New Brunswick, Canada
| | - Radu Christian Parscan
- Centre de Formation Médicale du Nouveau-Brunswick, Université de Sherbrooke, Moncton, New Brunswick, Canada
| | - Nicolas Crapoulet
- Atlantic Cancer Research Institute, Pavillon Hôtel-Dieu, Moncton, New Brunswick, Canada
| | - Abdullah Almaghraby
- Department of Pediatric Endocrinology, IWK Health Center, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Mouna Ben Amor
- Vitalité Health Network, Dr. Georges-L.-Dumont University Hospital Centre, Department of Medical Genetics, Moncton, New Brunswick, Canada
| |
Collapse
|
4
|
Léger JL, Soucy MN, Veilleux V, Foulem RD, Robichaud GA, Surette ME, Allain EP, Boudreau LH. Functional platelet-derived mitochondria induce the release of human neutrophil microvesicles. EMBO Rep 2022; 23:e54910. [PMID: 36125343 PMCID: PMC9638873 DOI: 10.15252/embr.202254910] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2022] [Revised: 09/01/2022] [Accepted: 09/06/2022] [Indexed: 09/19/2023] Open
Abstract
Inflammation is an essential process of host defense against infections, illness, or tissue damage. Polymorphonuclear neutrophils (PMN) are among the first immune cells involved in acute inflammatory responses and are on the front line in the fight against bacterial infections. In the presence of bacterial fragments, PMN release inflammatory mediators, enzymes, and microvesicles in the extracellular milieu to recruit additional immune cells required to eliminate the pathogens. Recent evidence shows that platelets (PLTs), initially described for their role in coagulation, are involved in inflammatory responses. Furthermore, upon activation, PLT also release functional mitochondria (freeMitos) within their extracellular milieu. Mitochondria share characteristics with bacterial and mitochondrial damage-associated molecular patterns, which are important contributors in sterile inflammation processes. Deep sequencing transcriptome analysis demonstrates that freeMitos increase the mitochondrial gene expression in PMN. However, freeMitos do not affect the mitochondrial-dependent increase in oxygen consumption in PMN. Interestingly, freeMitos significantly induce the release of PMN-derived microvesicles. This study provides new insight into the role of freeMitos in the context of sterile inflammation.
Collapse
Affiliation(s)
- Jacob L Léger
- Department of Chemistry and BiochemistryUniversité de MonctonMonctonNBCanada
- New Brunswick Center for Precision MedicineMonctonNBCanada
| | - Marie‐France N Soucy
- Department of Chemistry and BiochemistryUniversité de MonctonMonctonNBCanada
- New Brunswick Center for Precision MedicineMonctonNBCanada
| | - Vanessa Veilleux
- Department of Chemistry and BiochemistryUniversité de MonctonMonctonNBCanada
- New Brunswick Center for Precision MedicineMonctonNBCanada
- Atlantic Cancer Research InstituteMonctonNBCanada
| | - Robert D Foulem
- Department of Chemistry and BiochemistryUniversité de MonctonMonctonNBCanada
- New Brunswick Center for Precision MedicineMonctonNBCanada
| | - Gilles A Robichaud
- Department of Chemistry and BiochemistryUniversité de MonctonMonctonNBCanada
- New Brunswick Center for Precision MedicineMonctonNBCanada
- Atlantic Cancer Research InstituteMonctonNBCanada
| | - Marc E Surette
- Department of Chemistry and BiochemistryUniversité de MonctonMonctonNBCanada
- New Brunswick Center for Precision MedicineMonctonNBCanada
| | - Eric P Allain
- Department of Chemistry and BiochemistryUniversité de MonctonMonctonNBCanada
- New Brunswick Center for Precision MedicineMonctonNBCanada
- Atlantic Cancer Research InstituteMonctonNBCanada
- Department of Clinical GeneticsVitalité Health Network, Dr. Georges‐L.‐Dumont University Hospital CentreMonctonNBCanada
| | - Luc H Boudreau
- Department of Chemistry and BiochemistryUniversité de MonctonMonctonNBCanada
- New Brunswick Center for Precision MedicineMonctonNBCanada
| |
Collapse
|
5
|
LeBlanc S, Allain EP, Girouard G, Mallet M, Amor MB. Expanded phenotype of primary ciliary dyskinesia related to DRC1 pathogenic variant with dysmorphisms and vascular anomalies. Am J Med Genet A 2021; 188:965-969. [PMID: 34851034 DOI: 10.1002/ajmg.a.62586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Accepted: 11/10/2021] [Indexed: 11/09/2022]
Abstract
We present a case of a female diagnosed with primary ciliary dyskinesia (PCD) type 21 with non-previously reported extrapulmonary symptoms, including facial features and congenital vascular anomalies. Whole genome sequencing in our patient revealed a homozygous pathogenic variant in the DRC1 gene and no other notable structural nor punctual variants. This case demonstrates a unique clinical manifestation of PCD, which is possibly associated with the presence of a homozygous pathogenic DRC1 variant. Therefore, we suggest that analysis of DRC1 be considered with PCD type 21 when such features are present.
Collapse
Affiliation(s)
- Samuel LeBlanc
- Centre de Formation Médicale du Nouveau-Brunswick, Université de Sherbrooke, Moncton, New Brunswick, Canada
| | - Eric P Allain
- Department of Medical Genetics, Vitalité Health Network Dr. Georges-L.-Dumont University Hospital Centre, Moncton, New Brunswick, Canada.,Atlantic Cancer Research Institute, Pavillon Hôtel-Dieu, Moncton, New Brunswick, Canada.,Department of Chemistry and Biochemistry, New Brunswick Center for Precision Medicine, Université de Moncton, Moncton, New Brunswick, Canada
| | - Gabriel Girouard
- Department of Medical Microbiology and Infectious Diseases, Vitalité Health Network, Dr. Georges-L.-Dumont University Hospital Centre, Moncton, New Brunswick, Canada
| | - Marcel Mallet
- Department of Respirology, Vitalité Health Network, Dr. Georges-L.-Dumont University Hospital Centre, Moncton, New Brunswick, Canada
| | - Mouna Ben Amor
- Department of Medical Genetics, Vitalité Health Network Dr. Georges-L.-Dumont University Hospital Centre, Moncton, New Brunswick, Canada
| |
Collapse
|
6
|
Allain EP, Rouleau M, Le T, Vanura K, Villeneuve L, Caron P, Turcotte V, Lévesque E, Guillemette C. Inactivation of Prostaglandin E 2 as a Mechanism for UGT2B17-Mediated Adverse Effects in Chronic Lymphocytic Leukemia. Front Oncol 2019; 9:606. [PMID: 31334126 PMCID: PMC6621974 DOI: 10.3389/fonc.2019.00606] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2019] [Accepted: 06/19/2019] [Indexed: 01/22/2023] Open
Abstract
High expression of the metabolic enzyme UDP-glucuronosyltransferase UGT2B17 in chronic lymphocytic leukemia (CLL) cells was associated with poor prognosis in two independent studies. However, the underlying mechanism remains unknown. We hypothesized that UGT2B17 impacts intracellular levels of hormone-like signaling molecules involved in the regulation of gene expression in leukemic cells. We initially confirmed in a third cohort of 291 CLL patients that those with high UGT2B17 displayed poor prognosis (hazard ratio of 2.31, P = 0.015). Consistent with the unfavorable prognostic significance of elevated UGT2B17 expression in CLL patients, high UGT2B17 expression was associated with enhanced proliferation of MEC1 and JVM2 malignant B-cell models. Transcriptomic analyses revealed that high UGT2B17 was linked to a significant alteration of genes related to prostaglandin E2 (PGE2) and to its precursor arachidonic acid, both in cell models and a cohort of 448 CLL patients. In functional assays, PGE2 emerged as a negative regulator of apoptosis in CLL patients and proliferation in cells models, whereas its effect was partially abrogated by high UGT2B17 expression in MEC1 and JVM2 cells. Enzymatic assays and mass-spectrometry analyses established that the UGT2B17 enzyme inactivates PGE2 by its conjugation to glucuronic acid (GlcA) leading to the formation of two glucuronide (G) derivatives. High UGT2B17 expression was further associated with a proficient inactivation of PGE2 to PGE2-G in CLL patient cells and cell models. We conclude that UGT2B17-dependent PGE2 glucuronidation impairs anti-oncogenic PGE2 effects in leukemic cells, thereby partially contributing to disease progression in high UGT2B17 CLL patients.
Collapse
Affiliation(s)
- Eric P Allain
- Pharmacogenomics Laboratory, Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center - Université Laval, Laval University, Québec City, QC, Canada
| | - Michèle Rouleau
- Pharmacogenomics Laboratory, Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center - Université Laval, Laval University, Québec City, QC, Canada
| | - Trang Le
- Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
| | - Katrina Vanura
- Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
| | - Lyne Villeneuve
- Pharmacogenomics Laboratory, Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center - Université Laval, Laval University, Québec City, QC, Canada
| | - Patrick Caron
- Pharmacogenomics Laboratory, Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center - Université Laval, Laval University, Québec City, QC, Canada
| | - Véronique Turcotte
- Pharmacogenomics Laboratory, Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center - Université Laval, Laval University, Québec City, QC, Canada
| | - Eric Lévesque
- Division of Hemato-Oncology, Faculty of Medicine, CHU de Québec Research Centre - Université Laval, Laval University, Québec City, QC, Canada
| | - Chantal Guillemette
- Pharmacogenomics Laboratory, Faculty of Pharmacy, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center - Université Laval, Laval University, Québec City, QC, Canada.,Canada Research Chair in Pharmacogenomics, Québec City, QC, Canada
| |
Collapse
|
7
|
Allain EP, Venzl K, Caron P, Turcotte V, Simonyan D, Gruber M, Le T, Lévesque É, Guillemette C, Vanura K. Abstract 5237: Sex-dependent association of circulating sex steroids, pituitary hormones and treatment-free survival in patients with chronic lymphocytic leukemia. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-5237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Chronic lymphocytic leukemia (CLL) is the most frequent adult leukemia in the western world, and is not considered a hormone-regulated cancer but sex is a known risk factor with a significant male/female ratio (2:1) in its incidence with male patients more frequently developing progressive disease. We hypothesized that variable hormonal exposure may have a sexually dimorphic effect on CLL progression. However, a detailed evaluation of sex steroids and pituitary hormones in CLL patients is still lacking. In 156 CLL patients, we quantitatively profiled 15 circulating sex steroids (androgens, estrogens and progesterone) by sensitive and specific mass spectrometry and two pituitary hormones (luteinizing hormone (LH) and follicular secreting hormone (FSH)) by immunoassay. Data were analyzed separately by sex and in relation to treatment-free survival (TFS). Univariate and multivariate analyses of TFS were performed using Cox's proportional hazard model with hormone levels as continuous variables. Median age of CLL patients was 59.8 and 62.9 years for men and postmenopausal women, respectively. Common CLL prognostic markers had very similar frequencies between male and female cases. Median TFS was shorter for male patients than for women (80.7 vs. 135.0 months, P=0.033). Circulating profiles of hormones in CLL patients were significantly different from those of healthy donors whereas male cases had higher steroid levels than female patients. In male CLL cases, sex steroid levels were not significantly associated with TFS; however, higher LH levels were associated with shorter TFS in multivariate analyses with an adjusted hazard ratio (HRadj) of 2.11 (P = 0.004). In female CLL cases, high levels of potent androgens testosterone, dihydrotestosterone (DHT) and the sum of methoxy estrogens were significantly associated with improved TFS with HRadj values of 0.24 (P =0.007), 0.54 (P=0.023) and 0.31 (P =0.034), respectively. This study is the first to establish a link between outcome of CLL patients and circulating sex steroid and pituitary hormones, revealing a sex-specific hormonal imbalance associated with disease progression. This work was supported by a Canadian Institutes of Health Research grant to CG. EPA holds scholarships from Université Laval foundation - Leadership and sustainable development award and CHU de Québec foundation - Fernand Labrie excellence award.
Citation Format: Eric P. Allain, Karin Venzl, Patrick Caron, Véronique Turcotte, David Simonyan, Michaela Gruber, Trang Le, Éric Lévesque, Chantal Guillemette, Katrina Vanura. Sex-dependent association of circulating sex steroids, pituitary hormones and treatment-free survival in patients with chronic lymphocytic leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5237.
Collapse
Affiliation(s)
- Eric P. Allain
- 1Pharmacogenomics laboratory, Centre Hospitalier Universitaire de Québec (CHU) Research Center, Université Laval., Québec, Quebec, Canada
| | - Karin Venzl
- 2Division of Hematology and Hemostaseology, Department of Medecine I, Medical University of Vienna., Vienna, Austria
| | - Patrick Caron
- 1Pharmacogenomics laboratory, Centre Hospitalier Universitaire de Québec (CHU) Research Center, Université Laval., Québec, Quebec, Canada
| | - Véronique Turcotte
- 1Pharmacogenomics laboratory, Centre Hospitalier Universitaire de Québec (CHU) Research Center, Université Laval., Québec, Quebec, Canada
| | - David Simonyan
- 3Statistial and Clinical Research Platform, CHU de Québec Research Center., Québec, Quebec, Canada
| | - Michaela Gruber
- 2Division of Hematology and Hemostaseology, Department of Medecine I, Medical University of Vienna., Vienna, Austria
| | - Trang Le
- 2Division of Hematology and Hemostaseology, Department of Medecine I, Medical University of Vienna., Vienna, Austria
| | - Éric Lévesque
- 1Pharmacogenomics laboratory, Centre Hospitalier Universitaire de Québec (CHU) Research Center, Université Laval., Québec, Quebec, Canada
| | - Chantal Guillemette
- 1Pharmacogenomics laboratory, Centre Hospitalier Universitaire de Québec (CHU) Research Center, Université Laval., Québec, Quebec, Canada
| | - Katrina Vanura
- 2Division of Hematology and Hemostaseology, Department of Medecine I, Medical University of Vienna., Vienna, Austria
| |
Collapse
|
8
|
Allain EP, Venzl K, Caron P, Turcotte V, Simonyan D, Gruber M, Le T, Lévesque E, Guillemette C, Vanura K. Sex-dependent association of circulating sex steroids and pituitary hormones with treatment-free survival in chronic lymphocytic leukemia patients. Ann Hematol 2018; 97:1649-1661. [PMID: 29781039 PMCID: PMC6097785 DOI: 10.1007/s00277-018-3356-z] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Accepted: 04/28/2018] [Indexed: 02/06/2023]
Abstract
Chronic lymphocytic leukemia (CLL) is not considered a hormone-regulated cancer although sex is a recognized risk factor with men more frequently diagnosed and developing progressive disease. We hypothesized that variable hormonal exposure may have a sexually dimorphic influence on treatment-free survival (TFS). In 156 CLL cases, we quantitatively profiled 29 circulating steroids (progesterone, adrenal precursors, androgens, estrogens, and catechol estrogens) as well as luteinizing hormone (LH) and follicle-stimulating hormone. Median TFS was shorter for men than that for women (80.7 vs. 135.0 months, P = 0.033). Circulating hormone profiles in CLL patients were significantly different from those of healthy donors. In male CLL cases, higher LH levels were associated with shorter TFS (adjusted hazard ratio (HRadj) 2.11; P = 0.004). In female CLL cases, high levels of the potent androgens testosterone and dihydrotestosterone and the sum of methoxy estrogens were associated with an improved TFS with HRadj values of 0.24 (P = 0.007), 0.54 (P = 0.023), and 0.31 (P = 0.034), respectively. Reduced TFS was observed for women with CLL exhibiting high expression of the steroid-inactivating UGT2B17 enzyme. This study is the first to establish a link between the outcome of CLL patients, sex steroids, and pituitary hormones, revealing a sex-specific hormonal imbalance associated with disease progression.
Collapse
Affiliation(s)
- Eric P Allain
- Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, R4701.5, 2705 Blvd. Laurier, Québec, G1V 4G2, Canada
| | - Karin Venzl
- Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - Patrick Caron
- Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, R4701.5, 2705 Blvd. Laurier, Québec, G1V 4G2, Canada
| | - Véronique Turcotte
- Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, R4701.5, 2705 Blvd. Laurier, Québec, G1V 4G2, Canada
| | - David Simonyan
- Statistical and Clinical Research Platform, CHU de Québec Research Center, Québec, Canada
| | - Michaela Gruber
- Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - Trang Le
- Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - Eric Lévesque
- CHU de Québec Research Centre, Faculty of Medicine, Laval University, Québec, Canada
| | - Chantal Guillemette
- Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University, R4701.5, 2705 Blvd. Laurier, Québec, G1V 4G2, Canada. .,Canada Research Chair in Pharmacogenomics, Québec, Canada.
| | - Katrina Vanura
- Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
| |
Collapse
|
9
|
Labriet A, Allain EP, Rouleau M, Audet-Delage Y, Villeneuve L, Guillemette C. Post-transcriptional Regulation of UGT2B10 Hepatic Expression and Activity by Alternative Splicing. Drug Metab Dispos 2018; 46:514-524. [PMID: 29438977 DOI: 10.1124/dmd.117.079921] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2017] [Accepted: 01/31/2018] [Indexed: 12/17/2022] Open
Abstract
The detoxification enzyme UDP-glucuronosyltransferase UGT2B10 is specialized in the N-linked glucuronidation of many drugs and xenobiotics. Preferred substrates possess tertiary aliphatic amines and heterocyclic amines, such as tobacco carcinogens and several antidepressants and antipsychotics. We hypothesized that alternative splicing (AS) constitutes a means to regulate steady-state levels of UGT2B10 and enzyme activity. We established the transcriptome of UGT2B10 in normal and tumoral tissues of multiple individuals. The highest expression was in the liver, where 10 AS transcripts represented 50% of the UGT2B10 transcriptome in 50 normal livers and 44 hepatocellular carcinomas. One abundant class of transcripts involves a novel exonic sequence and leads to two alternative (alt.) variants with novel in-frame C termini of 10 or 65 amino acids. Their hepatic expression was highly variable among individuals, correlated with canonical transcript levels, and was 3.5-fold higher in tumors. Evidence for their translation in liver tissues was acquired by mass spectrometry. In cell models, they colocalized with the enzyme and influenced the conjugation of amitriptyline and levomedetomidine by repressing or activating the enzyme (40%-70%; P < 0.01) in a cell context-specific manner. A high turnover rate for the alt. proteins, regulated by the proteasome, was observed in contrast to the more stable UGT2B10 enzyme. Moreover, a drug-induced remodeling of UGT2B10 splicing was demonstrated in the HepaRG hepatic cell model, which favored alt. variants expression over the canonical transcript. Our findings support a significant contribution of AS in the regulation of UGT2B10 expression in the liver with an impact on enzyme activity.
Collapse
Affiliation(s)
- Adrien Labriet
- Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec Research Center and Faculty of Pharmacy, Québec, Canada Research Chair in Pharmacogenomics, Université Laval, Québec, Canada
| | - Eric P Allain
- Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec Research Center and Faculty of Pharmacy, Québec, Canada Research Chair in Pharmacogenomics, Université Laval, Québec, Canada
| | - Michèle Rouleau
- Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec Research Center and Faculty of Pharmacy, Québec, Canada Research Chair in Pharmacogenomics, Université Laval, Québec, Canada
| | - Yannick Audet-Delage
- Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec Research Center and Faculty of Pharmacy, Québec, Canada Research Chair in Pharmacogenomics, Université Laval, Québec, Canada
| | - Lyne Villeneuve
- Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec Research Center and Faculty of Pharmacy, Québec, Canada Research Chair in Pharmacogenomics, Université Laval, Québec, Canada
| | - Chantal Guillemette
- Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec Research Center and Faculty of Pharmacy, Québec, Canada Research Chair in Pharmacogenomics, Université Laval, Québec, Canada
| |
Collapse
|